Lymph Node Excision — Cost, Top Hospitals & Success Rates | MyMedicPlus

Lymph node excision (lymphadenectomy or lymph node biopsy) is a surgical procedure in which one or more lymph nodes are removed from the body. The procedure serves two principal purposes: diagnostic — obtaining tissue for histopathological examination when the cause of lymphadenopathy is uncertain — and therapeutic — removing lymph nodes involved by cancer as part of oncological staging and treatment.

Lymph nodes are small, bean-shaped structures of the immune system distributed throughout the body and grouped in regional clusters (axillary, cervical, inguinal, mediastinal, retroperitoneal, mesenteric). Enlarged lymph nodes may reflect reactive hyperplasia (infection or inflammation), primary lymphoid malignancy (lymphoma), or metastatic spread from a solid tumour in the drainage territory.

The procedure ranges from a simple excisional biopsy of a single palpable node under local anaesthesia in an outpatient setting, to an extensive radical lymph node dissection (such as axillary, cervical, or retroperitoneal) performed under general anaesthesia as part of a cancer operation. Sentinel lymph node biopsy (SLNB) — a minimally invasive technique using radioisotope and/or blue dye to identify the first draining node — has largely replaced routine complete axillary dissection in breast cancer and melanoma, substantially reducing morbidity.

Lymph node excision is performed for a broad range of diagnostic and oncological indications:

• Unexplained lymphadenopathy — persistent lymph node enlargement (greater than 1 cm lasting more than 3–6 weeks) not explained by obvious infection, particularly with constitutional symptoms (fever, night sweats, weight loss — 'B symptoms'); excisional biopsy is preferred over fine needle aspiration when lymphoma is suspected, as architecture is required for subtype classification
• Hodgkin and non-Hodgkin lymphoma — excisional biopsy is the diagnostic gold standard; architecture-preserving tissue is essential for accurate WHO classification and treatment planning
• Breast cancer (axillary staging) — sentinel lymph node biopsy (SLNB) is the standard for clinically node-negative early breast cancer; axillary lymph node dissection (ALND, levels I–III) is performed when nodes are involved (though evidence from ACOSOG Z0011 has restricted ALND indications)
• Melanoma — SLNB provides accurate nodal staging and guides prognosis; complete regional lymph node dissection (RLND) for macro-metastatic sentinel nodes has been questioned by the MSLT-II trial
• Head and neck cancers — selective or modified radical neck dissection as part of treatment; cervical nodal status is the single most important prognostic factor in most head and neck squamous cell carcinomas
• Testicular cancer — retroperitoneal lymph node dissection (RPLND) for staging and treatment of non-seminomatous germ cell tumours; laparoscopic and robotic RPLND reduce morbidity
• Colorectal cancer — mesenteric lymph node dissection is an integral part of colonic resection; nodal yield (minimum 12 nodes) is a quality indicator
• Tuberculous lymphadenitis and cat scratch disease — when FNA is non-diagnostic; excisional biopsy confirms the diagnosis and provides material for culture and sensitivity

The decision to perform lymph node excision is guided by clinical findings, imaging, and prior less invasive investigations:

• Failure of conservative observation — reactive lymphadenopathy in young patients with an identifiable infective cause is observed for 4–6 weeks; excision is indicated if the node fails to resolve or increases in size
• Non-diagnostic fine needle aspiration cytology (FNAC) — FNAC is the first-line investigation for palpable lymphadenopathy; excision is indicated when cytology is inconclusive, atypical, or suspicious for lymphoma (where architecture is required)
• Suspected lymphoma — constitutional B symptoms (fever, night sweats, weight loss of greater than 10%), rapidly enlarging nodes, mediastinal or retroperitoneal involvement, or clinical features strongly suggesting lymphoma are indications for excisional biopsy rather than FNAC
• Part of cancer staging operation — SLNB for breast cancer and melanoma, neck dissection for head and neck cancer, and RPLND for testicular cancer are performed as part of the primary oncological surgical procedure
• Pre-operative assessment — imaging-suspicious nodes (CT, PET-CT, MRI) that are not accessible to image-guided biopsy may require open surgical excision
• General fitness for anaesthesia — simple excisional biopsy is suitable for patients with significant comorbidities under local anaesthesia; radical dissection requires careful pre-operative cardiac and respiratory assessment

The type of lymph node procedure is tailored to the clinical indication, nodal location, and disease context:

• Excisional lymph node biopsy — complete surgical removal of a single accessible lymph node; preferred for suspected lymphoma (preserves nodal architecture); performed under local anaesthesia in an outpatient setting or under general anaesthesia for deeper nodes
• Sentinel lymph node biopsy (SLNB) — a radioisotope (technetium-99m labelled colloid) is injected around the tumour site 2–24 hours before surgery; blue dye (Patent Blue V or methylene blue) is injected intraoperatively; the first draining node (the sentinel node) is identified by a gamma probe and/or visual inspection and selectively removed; if the sentinel node is free of cancer, the remaining regional nodes are considered clear with greater than 95% accuracy
• Axillary lymph node dissection (ALND) — surgical removal of axillary level I–III nodes for breast cancer; standard when SLNB is positive in patients who do not meet ACOSOG Z0011 criteria; lymphedema risk 15–25%
• Modified radical neck dissection (MRND) — removal of cervical nodal levels I–V with preservation of the spinal accessory nerve, internal jugular vein, and sternocleidomastoid muscle; standard for head and neck squamous cell carcinoma; sacrifice of these structures (radical neck dissection) is now rare
• Retroperitoneal lymph node dissection (RPLND) — bilateral template RPLND for non-seminomatous testicular germ cell tumours; laparoscopic and robotic approaches reduce post-operative ileus and length of stay; nerve-sparing technique preserves ejaculatory function in the majority of patients
• Video-assisted mediastinoscopy (VAM) — access to mediastinal (paratracheal and subcarinal) nodes for staging of lung cancer or mediastinal lymphoma without thoracotomy; 98–99% sensitivity for mediastinal staging
• Image-guided core needle biopsy — CT or ultrasound-guided core biopsy is increasingly used as an alternative to open excision for accessible deep nodes (retroperitoneal, mediastinal); provides architecture-preserving tissue; preferred for lymphoma re-staging in some centres

Lymph node excision delivers diagnostic and therapeutic value across oncological and non-oncological conditions:

• Definitive tissue diagnosis — excisional biopsy provides the highest diagnostic yield for lymphoma subtyping (96–99%), which is essential for treatment selection; FNAC alone is inadequate for lymphoma diagnosis
• Accurate cancer staging — nodal status is the most important staging variable in breast cancer, melanoma, and many solid tumours; sentinel node and formal dissection results directly determine adjuvant therapy recommendations
• Therapeutic nodal clearance — removal of metastatic regional lymph nodes improves locoregional disease control and may contribute to overall survival, particularly in melanoma and head and neck cancers
• Prognosis clarification — SLNB result stratifies patients into low-risk (node-negative) and higher-risk (node-positive) groups; negative SLNB spares patients the morbidity of full regional dissection
• Minimal morbidity for SLNB — sentinel node biopsy has replaced axillary and inguinal dissection as first-line nodal surgery in breast cancer and melanoma; lymphedema risk is less than 5% with SLNB versus 15–25% with full dissection

The risk profile of lymph node excision depends heavily on the extent of surgery — from minimal risk for excisional biopsy to significant morbidity for radical dissection:

• Lymphedema — the most significant long-term complication; occurs in 15–25% of patients after axillary lymph node dissection for breast cancer and 5–10% after inguinal dissection; risk is increased by adjuvant radiotherapy to the axilla; ranges from mild pitting oedema to severe functional impairment of the limb; lifetime risk requires ongoing surveillance and patient education
• Seroma — fluid collection in the cavity left after node removal; the most common early complication after axillary dissection (10–20%); managed by aspiration; drains are routinely placed for 3–5 days post-dissection to reduce seroma formation
• Nerve injury — depends on site: intercostobrachial nerve (sensory loss to medial upper arm and axilla, very common after ALND); long thoracic nerve (winged scapula if damaged); thoracodorsal nerve (latissimus dorsi weakness); spinal accessory nerve in neck dissection (shoulder drop, less common with MRND); ilioinguinal or genitofemoral nerve with inguinal dissection
• Wound infection — occurs in 5–10% of dissection wounds; higher risk in obese patients and those receiving pre-operative chemotherapy
• Haematoma — post-operative bleeding into the surgical cavity; requires exploration and evacuation if expanding or causing neurovascular compromise; incidence approximately 1–3%
• Lymphocele — persistent collection of lymphatic fluid; common after pelvic and inguinal node dissection; most resolve spontaneously; large or infected lymphoceles may require percutaneous drainage or sclerotherapy
• Reduced range of movement — shoulder stiffness after axillary dissection or modified radical neck dissection; managed by physiotherapy and early mobilisation
• Chylous fistula — leakage of chyle from injured thoracic duct or major lymphatic trunks; rare but serious complication of mediastinal or retroperitoneal dissection; managed conservatively with a fat-free diet or, if refractory, surgically

Recovery and follow-up depend on the extent of the procedure and the underlying diagnosis:

• Excisional biopsy — day-case procedure; wound dressing changed at 48–72 hours; sutures or clips removed at 7–10 days; histopathology results typically available within 5–7 working days for routine processing, 2–3 days for urgent haematological tumours
• SLNB and ALND — drain management post-ALND (drain removed when output less than 30–50 mL/24 hours); shoulder physiotherapy begins within 24–48 hours; full range of motion exercises from day 7; return to light activity at 2–4 weeks; breast reconstruction or adjuvant treatment planning following pathology confirmation
• Neck dissection — drain removed day 2–4; early shoulder physiotherapy (spinal accessory nerve rehabilitation); speech and swallowing assessment if relevant structures are involved; wound care and scar massage from 3–4 weeks
• RPLND — nasogastric tube removed when bowel sounds return (1–3 days); early ambulation; return to normal diet and bowel function by day 4–7; hospital discharge day 4–7 for open RPLND, day 2–4 for laparoscopic/robotic; return to normal activity at 4–6 weeks
• Lymphedema surveillance — all patients undergoing ALND, inguinal, or pelvic dissection should receive baseline circumferential limb measurements and education on lymphedema prevention (avoiding cuts, burns, constriction on the affected limb); referral to a lymphedema physiotherapist if early signs develop
• Oncology follow-up — nodal histopathology directs further management: adjuvant chemotherapy, targeted therapy, immunotherapy, or radiotherapy as appropriate; CT, PET-CT, or MRI surveillance per site-specific oncology protocol

The cost of lymph node excision varies markedly by procedure complexity, oncological context, and country:

• Excisional biopsy (diagnostic) — India: $500–$2,000; UK/Europe: $2,000–$6,000; USA: $3,000–$8,000 (day case, local or general anaesthesia, includes histopathology)
• Sentinel lymph node biopsy (SLNB) — India: $1,500–$4,000; Germany/UK: $5,000–$10,000; USA: $8,000–$15,000; the radioisotope (lymphoscintigraphy) adds a nuclear medicine cost component
• Axillary lymph node dissection (ALND) — India: $3,000–$7,000 (as standalone or with breast surgery); USA: $12,000–$25,000 including operative and facility fees
• Modified radical neck dissection — India: $4,000–$8,000; Germany: $12,000–$20,000; USA: $20,000–$40,000; often combined with primary tumour resection (laryngectomy, parotidectomy), significantly increasing total cost
• Retroperitoneal lymph node dissection (RPLND) — India: $6,000–$12,000 (open) or $8,000–$15,000 (robotic); USA: $30,000–$60,000; robotic RPLND has a higher device cost but reduced hospital stay

Histopathology processing, immunohistochemistry, molecular profiling (e.g. FISH for lymphoma, MSI/MMR testing for colorectal cancer) add significantly to diagnostic cost and vary by laboratory. Oncology consultation, staging PET-CT, and subsequent treatment planning costs should be budgeted separately.

Less invasive diagnostic alternatives and non-surgical oncological strategies should be considered before proceeding to surgical excision:

• Fine needle aspiration cytology (FNAC) — first-line investigation for palpable lymphadenopathy; inexpensive, immediate result, minimal discomfort; sensitivity approximately 80–90% for carcinoma metastases; inadequate for lymphoma subclassification due to absence of architecture
• Ultrasound-guided core needle biopsy (CNB) — provides a tissue core (2–3 mm); allows immunohistochemistry and molecular analysis; increasingly replacing excisional biopsy for suspected lymphoma at experienced haematological centres (sensitivity 85–95%); preferred for deep or retroperitoneal nodes
• PET-CT staging — 18F-FDG PET-CT can accurately identify nodal involvement in many malignancies (sensitivity 80–90% for nodal metastases), potentially avoiding diagnostic surgery; used for staging lymphoma, lung cancer, melanoma, and other solid tumours
• Observation (watchful waiting) — for small (<1 cm), single, non-tender nodes in young patients with a recent infectious illness; a 4–6 week period of observation with appropriate antibiotic therapy if indicated is appropriate before proceeding to biopsy
• Endoscopic ultrasound (EUS) or endobronchial ultrasound (EBUS)-guided biopsy — for mediastinal and upper abdominal nodes; EBUS-TBNA has largely replaced mediastinoscopy for lung cancer staging at high-volume centres; minimally invasive, performed under conscious sedation
• Radiotherapy — definitive radiation to nodal regions is used as an alternative to surgery in some head and neck cancers, lymphoma (particularly early-stage Hodgkin lymphoma), and as adjuvant treatment for node-positive breast cancer, potentially avoiding extensive dissection
• Systemic therapy — in lymphoma, effective chemotherapy or immunotherapy can be commenced on core biopsy diagnosis without prior surgical staging in selected cases